- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoEuro 2024 predictions for top scorer, tournament winner and moreTop Soccer Predictions and Tips TodayWho will win Euro 2024 Golden Boot? Prediction, odds, favorites and expert tips for top goal scorer award | Sporting News United KingdomJimmy's Punt: Euro 2024 tips and predictions for matchday one - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- AB1338 FASTER DIAGNOSES OF RARE DISEASES BY USING DIAGNOSTIC DECISION SUPPORT SYSTEMS - IMPACT ON COSTS AND QUALITY OF LIFE
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
AB1338 FASTER DIAGNOSES OF RARE DISEASES BY USING DIAGNOSTIC DECISION SUPPORT SYSTEMS - IMPACT ON COSTS AND QUALITY OF LIFE
Abstract
Background: Around 300 million people worldwide suffer from a rare disease (Wakap et al., 2019). A helpful therapy is always based on a diagnosis. For rare diseases this often takes a long time. In the future, diagnostic decision support systems could be important tools for speeding up successful diagnoses.
Objectives: The aim of this study is to map the overall economic costs of our patient population from the time of initial contact with a doctor to successful diagnosis. Also, the cost-saving potential of an earlier diagnosis by complementing it with a diagnostic decision support system was modelled. In addition, the patient’s quality of life at the time of diagnosis is to be considered.
Methods: In this study, three points in time are relevant for our data collection: firstly, the patient’s initial contact with a physician, then the retrospectively modelled time stamp of correct diagnosis by using a diagnostic decision support system (Ronicke et al., 2019). Finally the time of correct diagnosis by the treating specialist was taken into account.
In previous studies direct (Willmen et al., 2021) and indirect (Willmen et al., 2023 (submitted)) costs were analysed. The data collection of our patient sample (n = 63) was carried out on their fundamental. Patients with data on all cost factors were selected from this database. This patient population was subdivided into two different disease groups (diseases of muscles and vessels).
For the data analysis all direct and indirect costs were calculated. Direct costs were extracted from the evaluation of doctors’ letters. Indirect costs were based on WHO’s Health and Work Performance Questionnaire (HPQ) data. Income levels, periods of unemployment, reduced working hours and early retirement were assessed using this questionnaire. The costs were standardised to annual costs per patient and 95% confidence intervals were calculated. Based on these results the annual costs for Germany were approximated. The SF-36 was used to assess patients’ quality of life at the time of diagnosis. The SF-36 scores were generated by counting physical and mental dimensions together. The resulting means were compared and tested with the norm population for statistical significance.
Results: The patients in the sample waited on average 5.5 years until a correct diagnosis was established. The longest waiting time was about 30 years. Overall, direct costs amounted to € 1,010,600.26 and indirect costs to € 4,138,413.91 from initial contact to diagnosis (Figure 1). The results suggest that the patient population incurred average annual direct costs of € 6271.02 (95% CI: € 4355.88; € 8186.16) (Figure 2). In addition, annual indirect costs per patient totalled € 12,327.76 (95%CI: € 6396.95; € 18,258.58). In comparison the time span from the initial contact with a physician until the correct prediction of the diagnosis using the diagnostic decision support system was considered. The patient population incurred average annual direct costs of € 2633.25 (95% CI: € 1810.83; € 3455.67) (Figure 2). Moreover, annual indirect costs per patient totalled € 7485.47 (95% CI: € 3840.96; € 11,129.99).
Potential cost savings using the diagnostic decision support system showed that direct costs of € 570,835.50 and indirect costs of € 2,128,662.73 could have been saved (Figure 1). Thus potential cost savings of € 60,555.73 per patient might be possible. Patients’ quality of life compared to the standard population showed that the patients were mentally healthy (52.7 ± 10; 51.2 ± 2) at the time of diagnosis, but physically more impaired (41.4 ± 12.3; 48,2 ± 5.6).
Conclusion: Diagnostic decision support systems combined with expert knowledge can speed up successful diagnoses of patients with rare diseases. This might have a positive impact on patients’ quality of life and lead to potential savings of direct and indirect costs.
REFERENCES: NIL.
- Download figure
- Open in new tab
- Download powerpoint
- Download figure
- Open in new tab
- Download powerpoint
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- Quality of life
- Economics
- Rare/orphan diseases
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Quality of life
- Economics
- Rare/orphan diseases
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens